Get started
Author

Yolanda M. Kirksey

Observed names: Y. Kirksey, Yolanda Kirksey
OpenAlex ID: A5083347722
NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
2016 · Deborah H. Charych, Ute Hoch, et al. · Clinical Cancer Research · 403
Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels
2008 · David R. Riddell, Hua Zhou, et al. · Journal of Neuroscience · 333
PDF
The LXR agonist TO901317 selectively lowers hippocampal Aβ42 and improves memory in the Tg2576 mouse model of Alzheimer's disease
2007 · David R. Riddell, Hua Zhou, et al. · Molecular and Cellular Neuroscience · 243
Enhanced clearance of Aβ in brain by sustaining the plasmin proteolysis cascade
2008 · J. Steven Jacobsen, Thomas A. Comery, et al. · Proceedings of the National Academy of Sciences · 146
NKTR-358: A novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases
2021 · Neha Dixit, Christie Fanton, et al. · Journal of Translational Autoimmunity · 54
PDF
Abstract 3755: Comprehensive antitumor immune activation by a novel TLR7/8 targeting agent NKTR-262 combined with CD122-biased immunostimulatory cytokine NKTR-214
2018 · Saul Kivimae, Marlene Hennessy, et al. · Cancer Research · 19
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two
2016 · Casey Ager, Matthew Reilley, et al. · Journal for ImmunoTherapy of Cancer · 17
PDF
Radiotherapy of Human Xenograft NSCLC Tumors in Nude Mice with a 90 Y-Labeled Anti-Tissue Factor Antibody
2005 · Baiyang Wang, Marc Berger, et al. · Cancer Biotherapy and Radiopharmaceuticals · 8
Abstract 558: Durable antitumor activity of the CD122-biased immunostimulatory cytokine NKTR-214 combined with immune checkpoint blockade
2016 · John L. Langowski, Rhoneil Pena, et al. · Cancer Research · 2
Abstract B057: The CD122-biased immunostimulatory cytokine NKTR-214 combined with checkpoint blockade leads to mobilization of antitumor immunity and synergistic activity
2016 · John L. Langowski, Murali Addepalli, et al. · Cancer Immunology Research · 1
Combination between a long-acting engineered cytokine (NKTR-214) and checkpoint inhibitors anti-CTLA-4 or anti-PD1 in murine tumor models.
2014 · Seema S. Kantak, Steve Lee, et al. · Journal of Clinical Oncology · 1
P4‐050: Dysregulation of brain ApoE and cholesterol metabolism in APP transgenic mice
2009 · Helen K. Warwick, Julius Jefferson, et al. · Alzheimer s & Dementia · 1
Data from NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
2023 · Deborah H. Charych, Ute Hoch, et al.
Figure S1 from NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
2023 · Deborah H. Charych, Ute Hoch, et al.
Figure S3 from NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
2023 · Deborah H. Charych, Ute Hoch, et al.
Supplemental Data from NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
2023 · Deborah H. Charych, Ute Hoch, et al.
Figure S4 from NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
2023 · Deborah H. Charych, Ute Hoch, et al.
Figure S2 from NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
2023 · Deborah H. Charych, Ute Hoch, et al.
Data from NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
2023 · Deborah H. Charych, Ute Hoch, et al.
Figure S4 from NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
2023 · Deborah H. Charych, Ute Hoch, et al.
Abstract B015: Antitumor activity of the CD122-biased immunostimulatory cytokine combined with immune checkpoint blockade requires innate and adaptive immunity
2016 · John L. Langowski, Seema S. Kantak, et al. · Cancer Immunology Research
Abstract 5032: Synergy between an engineered cytokine, NKTR-214, and CTLA-4 blockade in murine colon and breast tumor models
2014 · Steve Lee, Murali Addepalli, et al. · Cancer Research
P2‐159: Identification of HPA axis dysfunction in ApoE targeted replacement mice
2009 · Helen K. Warwick, Julius Jefferson, et al. · Alzheimer s & Dementia
O2‐04‐02: Astrocytes preferentially degrade apoE4: Impact on Aβ levels and neuronal plasticity in apoE targeted replacement mice
2009 · David Riddell, H. Zhou, et al. · Alzheimer s & Dementia
O4–01–06: Astrocytes have a reduced capacity to secrete apolipoprotein (APO) E4 leading to substantially reduced brain levels
2006 · David R. Riddell, Yolanda Kirksey, et al. · Alzheimer s & Dementia
Works count: 26
Citation count: 1,228
H-index: 8
I10-index: 7
Year
Topic
Type